Nyxoah(NYXH), Revenue Surges 347%......Accelerating Growth Through U.S. Performance and Middle East Market Expansion

American-listed biotech company Nyxoah (NYXH) has announced a series of major business updates, including equity disclosures, earnings releases, capacity expansion, and entry into the Middle East, accelerating global growth. Especially with commercialization results in the U.S. market, investor shareholding changes are also being monitored, drawing market attention.

On March 19 (local time), Nyxoah issued a transparency disclosure stating that Robert Taub and related legal entities hold a total of 4.3608 million shares, approximately 10.14% of voting rights. This stake consists of 4.3108 million shares and 50,000 warrants expiring in 2027-2028. The control structure is formed through Lovelgah SRL, wholly owned by BMI Estate, with Taub enjoying beneficial ownership and his children holding bare legal ownership. In a February disclosure, due to changes in the voting rights baseline, the shareholding ratio was adjusted to 9.99%.

Institutional investor activity is also evident. In January, BNP Paribas Asset Management disclosed holding 1.409791 million shares (3.28%), becoming a major shareholder. This change resulted from a merger of BNP Paribas Group’s asset management subsidiaries.

Performance shows a steep growth curve. In Q4 2025, Nyxoah’s net sales were approximately €5.6 million, with annual net sales reaching €10 million, representing increases of 347% and 122% year-over-year, respectively. Gross profit margin during the same period was about 64%. As of the end of 2025, cash and financial assets totaled approximately €48 million.

Notably, Q4 2025 marks the first full quarter after the company’s full entry into the U.S. market, during which 145 surgeons were trained and 57 hospital accounts activated. The company expects both Q1 and Q2 2026 to achieve about 25% sequential sales growth.

Global expansion strategies are also taking shape. In February, Nyxoah signed a business agreement with Sheikh Shakhbout Medical City in the UAE, aiming to expand the accessibility of the Genio sleep apnea treatment in the Middle East. The agreement includes establishing high-dose implant projects, setting up healthcare training centers, and conducting research on the links between chronic and metabolic diseases.

Capacity expansion investments are progressing simultaneously. The company plans to build a production facility in Wallonia, Belgium, featuring approximately 2,000 square meters of advanced cleanroom facilities. This move aims to meet growing demand in the U.S. and worldwide, strengthening the foundation for “margin improvement.”

Additionally, Nyxoah participated in the 2026 Oppenheimer Healthcare Conference to announce corporate strategies and held meetings with institutional investors. CEO Olivier Taelman emphasized U.S. market expansion and technological competitiveness through his speech.

Currently, Nyxoah is advancing three main initiatives: restructuring its equity structure, expanding market presence, and increasing production capacity. Industry analysts note: “Given that U.S. commercialization results are meeting initial expectations, future sales leverage and profitability improvements will be key variables influencing the company’s valuation.”